Cost Insights: Breaking Down Biogen Inc. and Catalent, Inc.'s Expenses

Biogen vs. Catalent: A Decade of Cost Dynamics

__timestampBiogen Inc.Catalent, Inc.
Wednesday, January 1, 201411710360001229100000
Thursday, January 1, 201512404000001215500000
Friday, January 1, 201614787000001260500000
Sunday, January 1, 201716300000001420800000
Monday, January 1, 201818163000001710800000
Tuesday, January 1, 201919554000001712900000
Wednesday, January 1, 202018052000002111000000
Friday, January 1, 202121097000002646000000
Saturday, January 1, 202222783000003188000000
Sunday, January 1, 202325334000003216000000
Monday, January 1, 202403428000000
Loading chart...

Infusing magic into the data realm

Cost Insights: Biogen Inc. vs. Catalent, Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. Over the past decade, Biogen Inc. and Catalent, Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, Biogen's cost of revenue increased by approximately 116%, peaking in 2023. Meanwhile, Catalent's expenses surged by nearly 162%, reflecting its aggressive expansion strategy. Notably, Catalent's costs surpassed Biogen's in 2020, maintaining a lead through 2023. This shift highlights Catalent's growing market presence. However, data for Biogen in 2024 is missing, leaving room for speculation on its future trajectory. As the pharmaceutical landscape continues to shift, these insights provide a window into the strategic financial maneuvers of two industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025